Esophageal Squamous Cell Carcinoma
Conditions
Interventions
The neoadjuvant chemotherapy combined with immunotherapy group:Patients with esophageal cancer received 2 to 6 cycles of neoadjuvant chemotherapy combined with immunotherapy before the operation.
The neoadjuvant radiotherapy and chemotherapy treatment group:Esophageal cancer patients received 4 cycles of neoadjuvant chemotherapy combined with radiotherapy before the operation.
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 80 years; 2. Clinically diagnosed with esophageal squamous cell carcinoma (ESCC), staged T1N1-3M0 or T2-4aN0-3M0; 3. Completed neoadjuvant therapy and underwent transthoracic esophagectomy; 4. Complete clinical data available, able to provide comprehensive treatment information.
Exclusion criteria
Exclusion criteria: 1. A history of malignant tumors; 2. Incomplete neoadjuvant treatment or salvage surgery; 3. Unable to assess treatment response due to missing examination data; 4. Missing clinical data or follow-up information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year progression-free survival rate and overall survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The recurrence and metastasis patterns 3 years after the surgery; | — |
Countries
China
Contacts
Public ContactJianhua Fu
Sun Yat-sen University Cancer Center
Outcome results
None listed